

**Supplementary Table 1.** Number of controls and cases of NHL and NHL subtypes used in this study from the International Lymphoma Epidemiology Consortium.

	<b>EpiLymph</b>	<b>BC</b>	<b>Mayo</b>	<b>UCSF1</b>	<b>UCSF2</b>	<b>NSW</b>	<b>NCI-SEER</b>	<b>Yale</b>	<b>TOTAL</b>
<b>B-cell NHL</b>	1024	489	940	303	1208	493	835	341	<b>5633</b>
<b>DLBCL</b>	361	149	178	101	451	173	317	151	1881
<b>FL</b>	187	167	244	114	291	205	256	115	1579
<b>SLL/CLL</b>	311	35	342	0	300	18	102	42	1150
<b>MCL</b>	48	40	54	0	35	21	35	0	233
<b>MZL</b>	106	59	60	0	89	50	72	33	469
<b>OTHER BNHL</b>	11	39	62	88	42	26	53	0	321
<b>Controls</b>	1402	549	1226	774	1293	498	748	544	<b>7034</b>

BC, British Columbia Study; Mayo, Mayo Clinic Study; UCSF1 and UCSF2, University of California, San Francisco, Studies 1 and 2; NSW, New South Wales Study; NCI-SEER, National Cancer Institute/Surveillance, Epidemiology, and End Results Study; Yale, Yale University Study.

**Supplementary Table 2.** List of selected single nucleotide polymorphisms genotyped in the studies of the International Lymphoma Epidemiology Consortium.

SNP	Gene(s)	Loc (GRCh37)	EpiLymph	BC	Mayo	UCSF1	UCSF2	NSW	NCI-SEER	Yale	# cases/ #controls
rs361525	TNF, LTA	6-31543101	1	1	1	0	0	1	1	1	3954/4791
rs731236	VDR	12-48238757	1	0	1	1	0	1	1	1	3518/4718
rs2305160	AC016738.3, NPAS2	2-101591304	1	1	1	0	1	0	0	0	3203/3878
rs737865	COMT, TXNRD2	22-19930121	1	1	1	1	1	0	0	0	3749/5036
rs1799929	NAT2	8-18257994	1	1	1	1	1	0	1	1	4827/6208
rs2582869	TNFSF13B	13-108912145	1	1	1	0	1	1	1	1	4649/5447
rs2308321	RP11-109A6.3, MGMT	10-131565064	1	1	1	0	1	1	1	1	4674/5461
rs187084	TWF2, TLR9, RP11-330H6.5	3-52261031	1	1	1	0	0	0	1	0	2990/3647
rs699517	ENOSF1, TYMS	18-673016	1	1	1	1	0	1	1	1	4322/5560
rs4774584	CYP19A1	15-51562007	1	1	1	0	1	0	0	0	3458/4348
rs1870049	CYP19A1	15-51625223	1	1	1	1	1	0	0	0	3752/5034
rs3824848	LMO2	11-33886547	1	1	1	0	0	1	1	1	3908/4750
rs4986782	NAT1	8-18080116	0	1	1	0	0	1	1	1	2979/3430
rs2227973	RAG2, RAG1	11-36597313	1	1	1	1	1	1	1	1	5060/6238
rs1137101	LEPR	1-66058513	1	1	1	1	1	0	0	0	3941/5135
rs16994592	CD70	19-6586498	1	1	1	0	0	1	1	1	3907/4752
rs4334089	RP11-89H19.1, VDR	12-48286015	1	0	1	1	1	0	0	0	3002/4011
rs3132453	BAG6, PRRC2A	6-31604044	1	1	1	1	1	1	1	1	4658/5919
rs13178127	XRCC4	5-82589432	1	1	1	0	0	1	1	1	3910/4754
rs1776948	SLC23A2	20-4931113	1	1	1	0	1	0	0	0	3448/4339
rs3769821	CASP8	2-202123430	1	1	1	0	0	1	1	1	3900/4753
rs2239704	TNF, LTA	6-31540141	1	1	HWE	0	0	1	1	1	2955/3498
rs2243263	IL4	5-132013299	1	1	1	0	0	1	1	1	3893/4746
rs4880	SOD2	6-160113872	0	1	1	1	0	0	1	1	2729/3592
rs909253	TNF, LTA	6-31540313	1	1	1	0	1	1	1	1	5046/6067
rs1805388	LIG4	13-108863591	0	1	0	0	0	1	1	1	1997/2190
rs1799930	NAT2	8-18258103	1	1	1	1	0	1	1	1	4302/5524
rs3172469	BCL6, RP11-211G3.2	3-187459088	1	1	1	0	1	1	1	1	4580/5373
rs12211228	IRF4	6-408833	1	1	1	0	0	1	1	1	3904/4750
rs4516035	RP11-89H19.1, VDR	12-48299826	1	0	1	1	1	0	0	0	3453/4588
rs485497	CTD-2049J23.2	3-159719132	1	1	1	0	1	1	1	1	4657/5451
rs10008492	-	4-38765720	0	1	1	0	1	1	1	1	3627/4045
rs1801274	FCGR2A	1-161479745	1	1	1	0	1	1	1	1	5225/6159

rs1785882	CASP1, CARD16	11-104923075	1	1	1	0	0	1	1	1	3877/4743
rs1800872	IL10	1-206946407	1	1	1	0	1	1	1	1	4940/5962
rs1800871	IL10	1-206946634	1	1	1	0	0	1	1	1	4043/4891
rs6736233	CASP8	2-202118974	1	1	1	0	0	1	1	1	3909/4755
rs3020314	ESR1	6-152270672	1	1	1	1	1	0	0	0	3941/5143
rs4833103	TLR1	4-38815502	1	1	1	0	1	1	1	1	4599/5351
rs1341239	-	6-22304204	1	1	1	1	1	0	0	0	3939/5141
rs2844482	TNF, LTA	6-31539767	1	1	1	0	1	1	1	1	5098/6024
rs1805087	MTR	1-237048500	0	1	1	1	1	1	1	1	4495/5426
rs1799931	NAT2	8-18258370	1	1	1	1	1	1	1	1	5318/6705
rs743572	CYP17A1, RP11-753C18.4, CYP17A1OS	10-104597152	1	1	1	1	0	0	0	0	2665/3780
rs696217	GHRL, SEC13, GHRLOS, TATDN2, GHRLOS2	3-10331457	1	1	1	0	1	0	0	0	3660/4467
rs3789068	BCL2L11	2-111909247	1	1	1	0	1	1	1	1	4641/5432
rs2297518	NOS2	17-26096597	1	1	1	0	1	1	1	1	4763/5526
rs36686	B3GNT3, INSL3	19-17922795	1	0	1	0	1	0	1	0	3383/3957
rs4680	COMT	22-19951271	1	1	1	1	1	0	1	0	4391/5557
rs1056932	BCL6, RP11-211G3.3	3-187447032	1	0	1	0	0	1	1	1	3528/4297
rs4986790	U6, TLR4	9-120475302	1	1	1	1	1	0	1	1	4569/5719
rs2849377	BCL2	18-60971644	1	1	1	0	0	1	1	1	3907/4753
rs3918241	MMP9	20-44635735	1	1	1	0	1	0	0	0	3411/4268
rs6596473	SLC23A1	5-138710576	1	1	1	0	1	0	0	0	3399/4252
rs1801133	MTHFR	1-11856378	1	1	1	1	1	1	1	1	5451/6771
rs1715364	SLC23A2	20-4898896	1	1	1	0	1	0	0	0	3507/4276
rs1143627	IL1B	2-113594387	1	1	1	1	0	1	1	1	4335/5581
rs1799724	TNF, LTA	6-31542482	1	0	0	0	0	1	1	1	2601/3104
rs1800630	TNF, LTA	6-31542476	0	1	1	0	0	1	HWE	1	2219/2756
rs17576	AL162458.1, RP11-465L10.10, MMP9	20-44640225	1	1	1	0	1	0	1	0	3876/4506
rs2899472	CYP19A1	15-51516055	1	1	1	0	1	0	1	0	4330/5097
rs1801280	NAT2	8-18257854	1	1	1	1	0	1	1	1	4286/5513
rs1800797	IL6, AC073072.5	7-22766221	HWE	1	1	0	0	1	1	1	3025/3489
rs4934436	-	10-90783320	1	1	1	0	1	1	1	1	4643/5432
rs1921310	TANK	2-162049201	1	1	1	0	0	1	1	1	3888/4719
rs2243248	IL4	5-132008644	1	1	1	0	0	1	1	1	4059/4913
rs16147	NPY	7-24323410	1	0	1	1	1	0	0	0	3256/4486

1 = SNP genotyped, 0 = SNP not genotyped, HWE = SNP not included in meta-analysis (Hardy-Weinberg p-value < 0.001)

BC, British Columbia Study; Mayo, Mayo Clinic Study; UCSF1 and UCSF2, University of California, San Francisco, Studies 1 and 2; NSW, New South Wales Study; NCI-SEER, National Cancer Institute/Surveillance, Epidemiology, and End Results Study; Yale, Yale University Study.

**Supplementary Table 3.** Meta-analysis results for candidate SNPs and risk of Non-Hodgkin Lymphoma. Table shows the association results for B-cell NHL and major B-cell NHL subtypes (DLBCL, FL, CLL) for all the SNPs that showed evidence of association to any B-cell NHL subtype at a random-effects meta-analysis p-value  $< 1.32 \times 10^{-3}$ .

SNP (A1/A2)	Gene(s)	Loc (GRCh37)	SUBTYPE	STUDIES	Random-effects p-value	Random-effects OR (95%CI)	Fixed-effects p-value	Fixed-effects OR (95%CI)	I <sup>2</sup> heterogeneity index	Cochran's Q test p-value
rs3789068 (G/A)	BCL2L11	2-111909247	B-NHL	7	<b>2.21E-11</b>	1.21 [1.15; 1.28]	2.21E-11	1.21 [1.15; 1.28]	0% [0; 62.9]	0.5808
			DLBCL	7	1.20E-02	1.15 [1.03; 1.28]	7.30E-04	1.15 [1.06; 1.25]	38.7% [0; 74.2]	0.1339
			FL	7	<b>1.61E-06</b>	1.24 [1.14; 1.35]	1.61E-06	1.24 [1.14; 1.35]	0% [0; 0]	0.9532
			CLL	7	<b>6.04E-04</b>	1.23 [1.09; 1.38]	1.13E-05	1.25 [1.13; 1.38]	18% [0; 61.8]	0.2927
rs3132453 (A/C)	BAG6, PRRC2A	6-31604044	B-NHL	8	<b>1.07E-09</b>	0.68 [0.60; 0.77]	1.07E-09	0.68 [0.60; 0.77]	0% [0; 40.8]	0.7984
			DLBCL	8	<b>1.89E-04</b>	0.70 [0.58; 0.84]	1.89E-04	0.70 [0.58; 0.84]	0% [0; 40.3]	0.8023
			FL	8	<b>1.26E-06</b>	0.59 [0.48; 0.73]	1.26E-06	0.59 [0.48; 0.73]	0% [0; 43.1]	0.7815
			CLL	7	1.32E-03	0.69 [0.55; 0.86]	1.32E-03	0.69 [0.55; 0.86]	0% [0; 22.1]	0.8956
rs2239704 (A/C)	TNF, LTA	6-31540141	B-NHL	5	<b>3.13E-06</b>	0.85 [0.79; 0.91]	3.13E-06	0.85 [0.79; 0.91]	0% [0; 0]	0.9804
			DLBCL	5	<b>8.98E-07</b>	0.78 [0.71; 0.86]	8.98E-07	0.78 [0.71; 0.86]	0% [0; 55.9]	0.7563
			FL	5	8.00E-02	0.91 [0.82; 1.01]	8.00E-02	0.91 [0.82; 1.01]	0% [0; 0]	0.9581
			CLL	5	4.51E-01	0.93 [0.76; 1.13]	8.47E-02	0.88 [0.77; 1.02]	31.6% [0; 73.8]	0.2111
rs909253 (G/A)	TNF, LTA	6-31540313	B-NHL	7	3.18E-02	1.07 [1.0; 1.14]	1.72E-02	1.07 [1.01; 1.13]	17% [0; 60.9]	0.2999
			DLBCL	7	<b>6.95E-04</b>	1.19 [1.08; 1.31]	2.20E-05	1.19 [1.10; 1.29]	30.4% [0; 70.3]	0.1957
			FL	7	8.49E-01	0.99 [0.91; 1.08]	8.49E-01	0.99 [0.91; 1.08]	0% [0; 26.9]	0.8797
			CLL	7	9.88E-01	1.00 [0.88; 1.13]	8.04E-01	1.01 [0.91; 1.12]	21.6% [0; 64.8]	0.2643
rs2844482 (A/G)	TNF, LTA	6-31539767	B-NHL	7	<b>1.07E-03</b>	1.13 [1.05; 1.22]	9.32E-04	1.13 [1.05; 1.22]	1.9% [0; 71.4]	0.4101
			DLBCL	7	<b>7.55E-04</b>	1.20 [1.08; 1.33]	7.55E-04	1.20 [1.08; 1.34]	0% [0; 58.1]	0.6518
			FL	7	7.77E-02	1.11 [0.99; 1.25]	7.77E-02	1.11 [0.99; 1.25]	0% [0; 67.6]	0.4922
			CLL	7	2.29E-01	1.08 [0.95; 1.23]	2.29E-01	1.08 [0.95; 1.23]	0% [0; 22.1]	0.8956
rs4833103 (C/A)	TLR1	4-38815502	B-NHL	7	<b>9.35E-04</b>	1.10 [1.04; 1.16]	9.35E-04	1.10 [1.04; 1.16]	0% [0; 54.9]	0.6925
			DLBCL	7	1.28E-01	1.10 [0.97; 1.24]	4.80E-02	1.09 [1.00; 1.18]	50.9% [0; 79.2]	0.057
			FL	7	<b>3.33E-03</b>	1.14 [1.04; 1.24]	3.33E-03	1.14 [1.04; 1.24]	0% [0; 38.3]	0.8286
			CLL	7	5.58E-01	1.04 [0.92; 1.17]	4.55E-01	1.04 [0.94; 1.15]	23.6% [0; 66.2]	0.2492

rs3769821 (G/A)	CASP8	2-202123430	B-NHL	6	<b>9.50E-04</b>	1.11 [1.04; 1.19]	9.50E-04	1.11 [1.05; 1.19]	0% [0; 71.8]	0.4805
			DLBCL	6	1.09E-01	1.08 [0.98; 1.19]	1.09E-01	1.08 [0.98; 1.19]	0% [0; 60.2]	0.671
			FL	6	3.25E-01	1.07 [0.94; 1.21]	2.42E-01	1.06 [0.96; 1.17]	35.9% [0; 74.4]	0.1678
			CLL	6	3.88E-02	1.21 [1.01; 1.46]	2.99E-03	1.19 [1.06; 1.33]	47.4% [0; 79.1]	0.0907
rs1799930 (A/G)	NAT2	8-18258103	B-NHL	7	4.72E-03	0.91 [0.86; 0.97]	4.72E-03	0.91 [0.86; 0.97]	0% [0; 70]	0.4404
			DLBCL	7	5.76E-01	0.97 [0.89; 1.07]	5.76E-01	0.97 [0.89; 1.07]	0% [0; 55.4]	0.6867
			FL	7	<b>9.77E-04</b>	0.85 [0.77; 0.93]	9.77E-04	0.85 [0.77; 0.93]	0% [0; 52.4]	0.7201
			CLL	6	3.50E-01	0.91 [0.74; 1.11]	3.58E-02	0.88 [0.78; 0.99]	51% [0; 80.5]	0.0695
rs10008492 (A/G)	-	4-38765720	B-NHL	6	<b>1.29E-03</b>	1.15 [1.06; 1.25]	1.48E-04	1.14 [1.06; 1.21]	36.2% [0; 74.6]	0.1651
			DLBCL	6	1.24E-01	1.10 [0.97; 1.24]	5.17E-02	1.10 [1.00; 1.22]	33.9% [0; 73.5]	0.1819
			FL	6	5.53E-02	1.19 [1.00; 1.41]	2.27E-03	1.1 [1.06; 1.25]	68.4% [25.5; 86.6]	0.0073
			CLL	6	4.83E-02	1.14 [1.00; 1.30]	4.14E-02	1.13 [1.00; 1.28]	7% [0; 76.4]	0.3719

**Supplementary Table 4.** Summary of Adjusted Odds Ratios from Meta-analysis for Risk of B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma and Marginal Zone Lymphoma associated with rs3789068 (A>G) (*BCL2L11*).

		<b>BNHL</b>	<b>FL</b>	<b>DLBCL</b>	<b>CLL</b>	<b>MCL</b>	<b>MZL</b>
<b>Meta-analysis</b>	<b>#Studies</b>	7	7	7	7	6	7
	<b>MAF ca/co</b>	0.51/0.46	0.52/0.46	0.50/0.46	0.52/0.46	0.50/0.47	0.50/0.46
	<b>Random-effects p-value</b>	2.21E-11	1.61E-06	1.20E-02	6.04E-04	2.91E-01	3.46E-02
	<b>Random-effects OR (95%CI)</b>	1.21 [1.15; 1.28]	1.24 [1.14; 1.35]	1.15 [1.03; 1.28]	1.23 [1.09; 1.38]	1.12 [0.91; 1.37]	1.18 [1.01; 1.37]
	<b>I<sup>2</sup> heterogeneity index</b>	0% [0; 62.9]	0% [0; 0]	38.7% [0; 74.2]	18% [0; 61.8]	0% [0; 53.6]	0% [0; 39.7]
	<b>Cochran's Q test p-value</b>	0.5808	0.9532	0.1339	0.2927	0.7412	0.8205
	<b>Random-effects p-value (95%CI)*</b>	9.28E-06	1.51E-02	2.32E-02	6.26E-04	2.27E-01	3.74E-01
	<b>Random-effects OR (95%CI)*</b>	1.21 [1.11; 1.32]	1.18 [1.03; 1.35]	1.19 [1.02; 1.38]	1.28 [1.11; 1.47]	1.21 [0.89; 1.65]	1.181 [0.88; 1.39]
<b>Epilymph</b>	<b>p-value</b>	3.25E-05	0.1172	0.0006399	0.00202	0.09266	0.5733
	<b>OR (95%CI)</b>	1.28 (1.14-1.44)	1.19 (0.96-1.48)	1.34 (1.13-1.58)	1.34 (1.11-1.61)	1.43 (0.94-2.17)	1.08 (0.82-1.44)
	<b>MAF ca/co</b>	0.51/0.45	0.50/0.45	0.52/0.45	0.52/0.45	0.54/0.45	0.47/0.45
<b>BC</b>	<b>p-value</b>	0.295	0.4342	0.6728	0.7868	0.9505	0.6028
	<b>OR (95%CI)</b>	1.10 (0.92-1.31)	1.10 (0.86-1.41)	1.06 (0.82-1.37)	1.07 (0.65-1.76)	0.99 (0.62-1.57)	1.11 (0.75-1.64)
	<b>MAF ca/co</b>	0.48/0.46	0.49/0.46	0.48/0.46	0.49/0.46	0.46/0.46	0.48/0.46
<b>Mayo</b>	<b>p-value</b>	4.49E-05	0.01275	0.4008	0.0005466	0.7692	0.08217
	<b>OR (95%CI)</b>	1.29 (1.14-1.45)	1.28 (1.05-1.56)	1.10 (0.83-1.38)	1.35 (1.14-1.61)	0.94 (0.64-1.40)	1.39 (0.96-2.00)
	<b>MAF ca/co</b>	0.54/0.47	0.53/0.47	0.50/0.47	0.55/0.47	0.47/0.47	0.55/0.47
<b>UCSF1</b>	<b>p-value</b>	-	-	-	-	-	-
	<b>OR (95%CI)</b>	-	-	-	-	-	-
	<b>MAF ca/co</b>	-	-	-	-	-	-
<b>UCSF2</b>	<b>p-value</b>	0.02755	0.06857	0.3552	0.08926	0.9747	0.2957
	<b>OR (95%CI)</b>	1.19 (1.02-1.40)	1.24 (0.989-1.56)	1.11 (0.89-1.38)	1.23 (0.97-1.57)	1.05 (0.05-20.05)	2.54 (0.44-14.52)
	<b>MAF ca/co</b>	0.49/0.45	0.49/0.45	0.48/0.45	0.50/0.45	0.5/0.45	0.67/0.45
<b>NSW</b>	<b>p-value</b>	0.1956	0.0246	0.4973	0.2456	0.9936	0.9703
	<b>OR (95%CI)</b>	1.13 (0.94-1.35)	1.32 (1.04-1.69)	1.09 (0.85-1.40)	0.66 (0.32-1.34)	1.00 (0.52-1.92)	0.99 (0.65-1.52)
	<b>MAF ca/co</b>	0.52/0.49	0.56/0.49	0.51/0.49	0.38/0.49	0.5/0.49	0.48/0.49
<b>NCI-SEER</b>	<b>p-value</b>	0.11	0.01962	0.7121	0.4536	0.3373	0.2337
	<b>OR (95%CI)</b>	1.13 (0.97-1.32)	1.30 (1.04-1.62)	0.96 (0.78-1.18)	1.13 (0.82-1.56)	1.27 (0.78-2.09)	1.25 (0.87-1.81)
	<b>MAF ca/co</b>	0.52/0.48	0.55/0.48	0.44/0.48	0.52/0.48	0.55/0.48	0.54/0.48

<b>Yale</b>	<b>p-value</b>	0.02013	0.2149	0.007205	0.6213	-	0.2625
	<b>OR (95%CI)</b>	1.28 (1.04-1.58)	1.21 (0.89-1.65)	1.47 (1.11-1.95)	0.89 (0.56-1.41)	-	1.35 (0.80-2.30)
	<b>MAF ca/co</b>	0.50/0.44	0.49/0.44	0.53/0.44	0.41/0.44	-	0.52/0.44

\*Meta-analysis results after excluding the studies that provided first evidence of the association of rs3789068 with lymphoma risk (NCI-SEER, NSW, Yale and Mayo) (<sup>17, 18</sup>).




**Supplementary Table 5.** Summary of Adjusted Odds Ratios from Meta-analysis for Risk of B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, and Marginal Zone Lymphoma associated with rs3132453 A>C (*PRRC2A*).

		<b>BNHL</b>	<b>FL</b>	<b>DLBCL</b>	<b>CLL</b>	<b>MCL</b>	<b>MZL</b>
<b>Meta-analysis</b>	<b>#Studies</b>	8	8	8	7	6	7
	<b>MAF ca/co</b>	0.047/0.066	0.041/0.066	0.045/0.066	0.048/0.068	0.069/0.070	0.061/0.068
	<b>Random-effects p-value</b>	1.07E-09	1.26E-06	1.89E-04	1.32E-03	7.92E-01	6.93E-01
	<b>Random-effects OR (95%CI)</b>	0.68 [0.60; 0.77]	0.59 [0.48; 0.73]	0.70 [0.58; 0.84]	0.69 [0.55; 0.86]	1.06 [0.69; 1.61]	0.93 [0.66; 1.32]
	<b>I<sup>2</sup> heterogeneity index</b>	0% [0; 40.8]	0% [0; 43.1]	0% [0; 40.3]	0% [0; 22.1]	0% [0; 67.7]	9% [0; 73.4]
	<b>Cochran's Q test p-value</b>	0.7984	0.7815	0.8023	0.8956	0.5592	0.3599
	<b>Random-effects p-value (95%CI)*</b>	1.41E-08	1.89E-05	1.11E-03	1.58E-02	3.29E-01	7.97E-01
	<b>Random-effects OR (95%CI)*</b>	0.66 [0.57; 0.76]	0.59 [0.46; 0.75]	0.71 [0.58; 0.87]	0.69 [0.51; 0.93]	0.75 [0.41; 1.34]	0.94 [0.60; 1.48]
<b>Epilymph</b>	<b>p-value</b>	0.006331	0.0818	0.1139	0.2314	0.273	0.07432
	<b>OR (95%CI)</b>	0.67 (0.52-0.90)	0.60 (0.34-1.07)	0.72 (0.48-1.08)	0.77 (0.50-1.18)	0.52 (0.16-1.67)	0.47 (0.20-1.08)
	<b>MAF ca/co</b>	0.040/0.058	0.035/0.058	0.042/0.058	0.045/0.058	0.031/0.058	0.028/0.058
<b>BC</b>	<b>p-value</b>	0.03172	0.3497	0.01884	0.09323	0.3484	0.7646
	<b>OR (95%CI)</b>	0.67 (0.47-0.97)	0.79 (0.478-1.30)	0.46 (0.24-0.88)	0.18 (0.025-1.33)	0.62 (0.22-1.70)	1.11 (0.55-2.26)
	<b>MAF ca/co</b>	0.060/0.089	0.071/0.089	0.041/0.089	0.089/0.081	0.054/0.089	0.098/0.089
<b>Mayo</b>	<b>p-value</b>	0.0153	0.02238	0.06211	0.03401	0.1694	0.7529
	<b>OR (95%CI)</b>	0.75 (0.59-0.95)	0.61 (0.40-0.93)	0.63 (0.39-1.02)	0.68 (0.48-0.97)	1.52 (0.84-2.78)	0.90 (0.45-1.78)
	<b>MAF ca/co</b>	0.063/0.082	0.051/0.082	0.053/0.082	0.058/0.082	0.120/0.082	0.075/0.082
<b>UCSF1</b>	<b>p-value</b>	0.006328	0.04253	0.3327	-	-	-
	<b>OR (95%CI)</b>	0.40 (0.20-0.77)	0.29 (0.09-0.96)	0.65 (0.27-1.56)	-	-	-
	<b>MAF ca/co</b>	0.020/0.044	0.014/0.044	0.031/0.044	-	-	-
<b>UCSF2</b>	<b>p-value</b>	0.02252	0.0131	0.3952	0.1678	0.9948	0.2728
	<b>OR (95%CI)</b>	0.64 (0.44-0.94)	0.41 (0.20-0.83)	0.80 (0.49-1.33)	0.64 (0.34-1.20)	1.102e-06 (0-inf)	3.47 (0.38-32.10)
	<b>MAF ca/co</b>	0.041/0.058	0.032/0.058	0.045/0.058	0.044/0.058	0/0.058	0.167/0.058
<b>NSW</b>	<b>p-value</b>	0.4167	0.3514	0.8833	0.9965	0.9964	0.3419
	<b>OR (95%CI)</b>	0.81 (0.49-1.35)	0.71 (0.34-1.47)	0.95 (0.46-1.96)	1.932e-08 (0-inf)	2.378e-08 (0-inf)	1.59 (0.61-4.13)
	<b>MAF ca/co</b>	0.043/0.053	0.038/0.053	0.05/0.053	0/0.053	0/0.053	0.083/0.053
<b>NCI-SEER</b>	<b>p-value</b>	0.006278	0.0217	0.03432	0.3231	0.8504	0.9861
	<b>OR (95%CI)</b>	0.65 (0.48-0.88)	0.55 (0.33-0.92)	0.61 (0.39-0.96)	0.71 (0.36-1.40)	1.09 (0.43-2.75)	0.99 (0.51-1.92)
	<b>MAF ca/co</b>	0.050/0.078	0.043/0.078	0.046/0.078	0.056/0.078	0.086/0.078	0.078/0.078

<b>Yale</b>	<b>p-value</b>	0.1295	0.1631	0.7774	0.3315	-	0.2561
	<b>OR (95%CI)</b>	0.67 (0.41-1.12)	0.54 (0.23-1.28)	0.91 (0.49-1.70)	0.49 (0.12-2.05)	-	0.32 (0.04-2.31)
	<b>MAF ca/co</b>	0.038/0.055	0.031/0.055	0.051/0.055	0.028/0.055	-	0.018/0.055

\*Meta-analysis results after excluding the study that provided first evidence of the association of rs3132453 with lymphoma risk (Mayo) (<sup>11</sup>).

**Supplementary Figure 1.** Heterogeneity among most common B-cell NHL subtypes for rs3789068 (*BCL2L11*) rs3132453 (*PRRC2A*) and the TNF/LTA SNPs rs2239704, rs909253 and rs284482



**B-cell NHL subtype**

DLBCL  
FL  
CLL

**Fixed effect model**  
**Random effects model**  
*I-squared=0%, p=0.4295*

